AI-powered nanodelivery ushers in a healthier future. Jitai Technology is an AI-driven biotechnology company specializing in the innovation of nanomaterials, with a focus on leveraging targeted drug delivery and discovery technologies to accelerate the development of breakthrough therapies for patients across critical disease areas. The company was co-founded by Dr. Hongmin Chen, a member of the U.S. National Academy of Engineering, along with MIT scientists Dr. Caida Lai and Dr. Wenshou Wang. Jitai has successfully developed an AI-based nanodelivery platform—a large-scale foundational model—and three core solutions: AiLNP (an AI-powered nanoparticle delivery system design platform), AiRNA (an AI-driven mRNA sequence design platform), and AiTEM (an AI-powered small-molecule formulation design platform). The company now possesses the capability to achieve precise, organ- and cell-specific LNP-mediated delivery to key tissues and cell types, including the liver, lungs, muscles, and immune cells. It has made groundbreaking advances in overcoming the challenges of multi-organ and multi-tissue targeting, thereby creating therapeutic opportunities for oncology, metabolic disorders, autoimmune diseases, and neurodegenerative conditions.